20
Participants
Start Date
November 30, 2009
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
CYT997
Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
Carboplatin
Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
Royal North Shore Hospital, St Leonards
Monash Medical Centre, Melbourne
Gold Coast Hospital, Southport
Flinders Medical Centre, Bedford Park
Lead Sponsor
Gilead Sciences
INDUSTRY